Diffusion Pharmaceuticals Inc. (DFFN) |
| 4.4 0.41 (10.28%) 08-16 16:00 |
| Open: | 4.23 |
| High: | 5.19 |
| Low: | 4.165 |
| Volume: | 349,445 |
| Market Cap: | 9(M) |
| PE Ratio: | -0.62 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 14.37 |
| 52w Low: | 4.139999 |
As a biopharmaceutical enterprise, Diffusion Pharmaceuticals Inc. concentrates on pioneering new treatments that bolster the body's efficiency in oxygen distribution. The company's flagship investigational therapy is Trans Sodium Crocetinate, which is formulated to facilitate the spread of oxygen into tissues. This compound is additionally under development for its application in addressing COVID-19. Headquartered in Charlottesville, Virginia, Diffusion Pharmaceuticals Inc. was established in 2001.
Financials
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Company news
Thu, 08 Feb 2024
Vertex co-founder Josh Boger joins Boston biotech working on dementia drug - The Business Journals
Tue, 15 Aug 2023
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma - Yahoo Finance
Sun, 24 Apr 2022
U.S stock market gainers for the week - Nairametrics
Thu, 25 Feb 2021
Millionaire Mentor Update: Giving Back and Taking Profits - timothysykes.com
Wed, 18 Jan 2017
DFFN: Diffusion Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Mon, 19 Oct 2026
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
